Thursday, 10 October 2019

10.00  Registration opens

12.00 – 14.00  ESU Course
New challenges and unmet needs in basic science and histopathology to address the clinical management of renal malignancies
Chair:  M. Hora, Plzen (CZ)

12.00 – 12.05  European School of Urology: A unique possibility for urological education
M. Hora, Plzen (CZ)

12.05 – 12.30  Current indications and challenges for the treatment of renal cell carcinoma according to the EAU guidelines
1. Therapeutic options in localized disease (surgery, ablative techniques, active surveillance); 2. Systemic treatment in metastatic disease
M. Hora, Plzen (CZ)

12.30 – 13.30  Histopathological classification and molecular pathology of renal cell tumors: basics and clinical value for decision making
1. Histopathological and molecular characterization of renal cell carcinoma
   A. Hartmann, Erlangen (DE)
2. Incorporation of genetic and molecular profiling into clinical decision-making in patients with kidney cancer: Ready for prime time?
   R. Leao, Coimbra (PT)

13.30 – 14.00  Discussion and close

**Aims and objectives**
The aim of this ESU course is to describe the current indications for the treatment of renal malignancies and to provide an update on the histopathological features and molecular patterns of kidney cancer. The course will also focus on the opportunities for the introduction of genetic and molecular profiling in the daily clinical practice of patients with renal cell carcinoma.

14.30 – 14.45  Opening
Carmen Jeronimo, Porto (PT)  Meeting Chair
Kerstin Junker, Homburg (DE)  ESUR Chair
Rodolfo Montironi, Ancona (IT)  ESUP Chair
Rui Henrique, Porto (PT)  Director IPO Porto

14.45 – 16.10  Session 1
Microenvironment, metabolism and epigenetic reprogramming
Chairs:  Guido Jenster, Rotterdam (NL)
         Gabri van der Pluijm, Leiden (NL)

14.45 – 15.10  Phenotype-independent DNA methylation changes in prostate cancer
Norman Maitland, York (GB)
15.10 – 15.30  The tumour-microenvironment as a barrier or enabler of the host immune response  
Gabriel Malouf, Strasbourg (FR)

15.30 – 15.50  MicroRNA expression and activity in the prostate cancer tumour microenvironment  
Shawn Lupold, Baltimore (US)

15.50 – 16.10  The multifunctional role of the enzyme APE1/Ref-1 in bladder cancer: Growth, cell survival and muscle invasion  
Travis Jerde, Indianapolis (US)

16.10 – 16.40  Break

16.40 – 17.40  Session 2  
Translational research in bladder dysfunction  
Chairs: Francisco Cruz, Porto (PT)  
Alexandra Masson-Lecomte, Paris (FR)  
Elena Martens-Uzunova, Rotterdam (NL)

16.40 – 17.00  RNA profiling in bladder pathologies  
Katia Monastyrskaya, Berne (CH)

17.00 – 17.20  Neurotrophins and stress in bladder pain  
Ana Charrua, Porto (PT)

17.20 – 17.40  Regulating axonal growth for spinal cord regeneration  
Martin Schwab, Zurich (CH)

17.40 – 18.30  Short presentations 1  
Chairs: Francisco Cruz, Porto (PT)  
Alexandra Masson-Lecomte, Paris (FR)  
Elena Martens-Uzunova, Rotterdam (NL)

17.40 – 17.50  01 Study on the possible interactions between FGFRL1- and AR-regulated mechanisms in prostate cancer  
Syeda Afshan, Turku (FI)

17.50 – 18.00  02 Mechanisms of ETS family transcription factors that promote prostate cancer  
Peter Hollenhorst, Bloomington (US)

18.00 – 18.10  03 Mitochondrial complex I gene mutations drive metabolic reprogramming in prostate cancer  
Helmut Klocker, Innsbruck (AT)

18.10 – 18.20  04 Metabolic reprogramming and epigenetic landscape: an interplay to renal cell carcinoma aggressiveness promotion  
Vera Miranda-Gonçalves, Porto (PT)

18.20 – 18.30  05 The adipose tissue that surrounds the prostate gland exhibits traits of hypoxic state that could contribute to its role in prostate cancer progression  
Mathieu Roumiguie, Toulouse (FR)
Friday, 11 October 2019

08.30 – 09.40  Session 3
Epidrugs: From basics to clinical trials
Chairs: Jocelyn Ceraline, Strasbourg (FR)
       Carmen Jeronimo, Porto (PT)
       Antonia Vlahou, Athens (GR)

08.30 – 08.50  Novel approaches to targeting the androgen receptor in CRPC
Ganesh Raj, Dallas (US)

08.50 – 09.15  Clinical trials on epigenetic therapies for urological tumours
Simon Crabb, Southampton (GB)

09.15 – 09.40  Epidrugs designing
Paola Arimondo, Paris (FR)

09.40 – 10.20  Session 4
Immuno-oncology: pre-clinical and clinical trials: Pre-clinical studies
Chairs: Jocelyn Ceraline, Strasbourg (FR)
       Carmen Jeronimo, Porto (PT)
       Antonia Vlahou, Athens (GR)

09.40 – 10.00  Inhibition of a G9a/EZH2 network triggers an immune-mediated bladder cancer regression
Jesus Paramio, Madrid (ES)

10.00 – 10.20  Oncolytic viruses as a kick-start for immunotherapy
Gabri van der Pluijm, Leiden (NL)

10.20 – 10.50  Break

10.50 – 11.50  Session 5
Immuno-oncology: Preclinical and clinical trials: Clinical trials
Chairs: Imran Ahmad, Glasgow (GB)
       Allen Gao, Sacramento (US)
       Mariangela Mancini, Padua (IT)

10.50 – 11.10  Mechanisms of action and resistance to BCG immunotherapy: New developments
Joost Boormans, Rotterdam (NL)

11.10 – 11.30  Immunotherapy combinations and sequences in urothelial cancer: Facts and hopes
Yohann Loriot, Villejuif (FR)

11.30 – 11.50  New combination partners of IO (eg. anti-angiogenesis) in RCC (preclinical concept and recent clinical studies)
Andreas Pircher, Innsbruck (AT)

11.50 – 12.30  Short presentations 2
Chairs: Imran Ahmad, Glasgow (GB)
       Allen Gao, Sacramento (US)
       Mariangela Mancini, Padua (IT)

11.50 – 12.00  06 Artesunate reduces cell growth and induces ferroptosis in therapy-resistant renal cell carcinoma cells
Eva Juengel, Mainz (DE)

12.00 – 12.10  07 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts
Egbert Oosterwijk, Nijmegen (NL)
12.10 – 12.20  O8 Clinical activity of vofatamab, an FGFR3 selective antibody in combination with pembrolizumab in metastatic urothelial carcinoma (mUC), updated follow up results from the interim analysis of FIERCE-22
Esteban Abella, San Leandro (US)

Rafael Stroggilos, Athens (GR)

12.30 – 13.30 Lunch

13.30 – 15.00 Poster session 1
Poster numbers P1 – P40

14.45 – 15.00 Break

15.00 – 16.30 Session 6
Panel session: Local therapy in metastatic prostate cancer
Chairs: Isabel Heidegger, Innsbruck (AT)
        Hing Leung, Glasgow (GB)

15.00 – 15.15 Radiotherapy
To be confirmed

15.15 – 15.30 Surgery
Matthias Saar, Homburg (DE)

15.30 -15.45 Hormonal therapy
Igor Tsaur, Mainz (DE)

15.45 – 16.05 Role of primary tumour for metastasis development and therapy response (including exosomes)
Bruno Costa-Silva, Lisbon (PT)

16.05 – 16.30 Panel discussion

16.30 – 17.30 Short presentations 3
Chairs: Egbert Oosterwijk, Nijmegen (NL)
        Martin Puhr, Innsbruck (AT)

16.30 – 16.50 Role of prostate derived Ets factor in prostate cancer
Hari Koul, Shreveport (US)

16.50 – 17.00 O10 A transcription factor activity profile as a prognostic signature for androgen deprivation therapy resistance predisposition in prostate cancer patients
Mario Cangiano, Leiden (NL)

17.00 – 17.10 O11 Cytoreductive primary tumor removal slows down disease progression in an orthotopic xenograft model of prostate cancer
Johannes Linxweiler, Homburg (DE)

17.10 – 17.20 O12 Tumor-secreted exosomal miR-424: impact on prostate tumorigenesis in mouse models and patients
Giuseppina Carbone, Bellinzona (CH)

17.20 – 17.30 O13 A duplex quantitative real-time PCR assay for the detection of small non-coding RNA in urinary extracellular vesicles
Elena Martens-Uzunova, Rotterdam (NL)
Saturday, 12 October 2019

08.45 – 09.50  Session 7
Molecular subtypes and therapeutics
Chairs: Kerstin Junker, Homburg (DE)
Holger Moch, Zurich (CH)
Rodolfo Montironi, Ancona (IT)

08.45 – 09.10 Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal
Scott Shepherd, London (GB)

09.10 – 09.30 Histopathological subtypes in RCC: consequences for systemic therapy
Holger Moch, Zurich (CH)

09.30 – 09.50 Sequencing of prostate cancers identifies new cancer genes, routes of progression and
drug targets
David Wedge, Oxford (GB)

09.50 – 10.30 Short presentations 4
Chairs: Kerstin Junker, Homburg (DE)
Holger Moch, Zurich (CH)
Rodolfo Montironi, Ancona (IT)

09.50 – 10.00 O14 Urothelial bladder cancer risk patterns according to tumor taxonomic subtypes
Raquel Benitez Dorta, Madrid (ES)

10.00 – 10.10 O15 Immune infiltrate, immune checkpoints and mismatch repair proteins in
testicular germ cell tumors: A role in prognosis and patient outcome
Joao Lobo, Porto (PT)

10.10 – 10.20 O16 Immunogenomic analysis reveals that tumor aggressiveness is associated with
a decreased CD8 T cell signature in an in vivo prostate cancer model
Merle Van Gelder, Rotterdam (NL)

10.20 – 10.30 O17 The mTOR kinase directly regulates FBP1 gene expression via interaction with
SWI/SNF chromatin remodeling complex in clear cell renal cell carcinoma (ccRCC)
Elzbieta Sarnowska, Warsaw (PL)

10.30 – 11.00 Break

11.00 – 11.30 Session 8
Data protection regulation and ethics
Chairs: Yves Allory, Paris (FR)
Natasha Kyprianou, New York (US)

11.00 – 11.30 Open consent, biobanking and data protection law: Can open consent be ‘informed’
under the data protection regulation?
Dara Hallinan, Karlsruhe (DE)

11.30 – 12.30 Short presentations 5
Chairs: Yves Allory, Paris (FR)
Natasha Kyprianou, New York (US)

11.30 – 11.40 O18 A novel calcium-mediated epithelial-to-mesenchymal transition pathway
controlled by lipids: an opportunity for prostate cancer adjuvant therapy
Fanny Bery, Tours (FR)

11.40 – 11.50 O19 Biomarker exploration of extracellular vesicles in renal cell carcinoma
Dirk Himbert, Homburg (DE)

11.50 – 12.00 O20 m6A-regulated long non-coding RNAs in prostate cancer
Daniela Barros Silva, Porto (PT)

12.00 – 12.10 O21 Macrophage-associated changes in peri-prostatic adipose tissue: a novel local
driver of prostate tumorigenesis?
Laura Martinez Campesino, Sheffield (GB)
12.10 – 12.20  O22  Comprehensive multi-omic profiling of tumor endothelial cells of prostate tissue
Andreas Pircher, Innsbruck (AT)

12.20 – 12.30  O23  Effects of systemic glucocorticoid administration on stromal and epithelial GR signalling with consequences for prostate cancer progression
Martin Puhr, Innsbruck (AT)

12.30 – 13.30  Lunch

13.30 – 15.00  Poster session 2
Poster numbers P41 – P76 and LB1 – LB7

14.45 – 15.00  Break

15.00 – 15.30  Dominique Chopin Award
Presented by Kerstin Junker, Homburg (DE)

Dominique Chopin Lecture
Is there still room for improvement in the clinical targeting of the androgen receptor: A molecular study
Frank Claessens, Leuven (BE)

15.30 – 16.00  ARTP Award and closing remarks